Abstract
Spinal muscular atrophy (SMA) is a severe neurodegenerative disease caused by defects in the survival motor neuron 1 (SMN1) gene. The wide variability in SMA severity is partially explained by an inverse correlation with copy number variation of the second human SMN gene (SMN2). Nevertheless, significant variability in severity and treatment response remains unexplained, prompting a search for accessible biomarkers that could explain and predict this variability. DNA methylation of SMN2 has been proposed as one such biomarker, but comprehensive evidence and analyses are lacking. Here, we combined long-read nanopore sequencing with targeted bisulfite sequencing to enable high-resolution analysis of SMN2-specific methylation patterns. We observed tissue-specific variation in DNA methylation across the entire 30 kb SMN2 gene in 29 patients analyzed by long-read nanopore sequencing, identifying variable methylation patterns in the promoter, introns, and 3’ UTR. Subsequent targeted analysis of these regions by bisulfite sequencing of blood-derived DNA in 365 SMA patients showed no association between SMN2 methylation and disease severity or treatment response, excluding blood methylation patterns as predictive biomarkers. However, we discovered significant age-associated variation in SMN2 methylation, particularly in intron 1 and the 3’ UTR, highlighting DNA methylation as a possible modifier of SMN expression during development and aging. Our approach provides a broadly applicable strategy for detailed but cost-effective and high-throughput characterization of DNA methylation in other genes and diseases, including complex genetic regions.
Competing Interest Statement
WvR has sponsored research agreements with Biogen and Astra Zeneca. JHV reports to have sponsored research agreements with Biogen, Eli Lilly and Astra Zeneca. The other authors report no competing interests.
Funding Statement
This work was supported by grants from Stichting Spieren voor Spieren (to WLvdP), the European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant (H2020 Marie Skłodowska-Curie Actions) agreement no. 956185 (SMABEYOND ITN to WLvdP, EJNG) and Prinses Beatrix Spierfonds (W.OB21-01 to EJNG). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement no 772376 - EScORIAL). We acknowledge the Utrecht Sequencing Facility (USEQ) for providing sequencing service and data. USEQ is subsidized by the University Medical Center Utrecht and The Netherlands X-omics Initiative (NWO project 184.034.019).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethical Committee of the University Medical Center Utrecht gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request but are not publicly available due to privacy restrictions. The code used for analyses in this study is available at: https://github.com/ghaaften/SMA_DNA_methylation.
